Experience

Blue Owl Capital Extends up to $500 Million in Senior Secured Credit to Madrigal Pharmaceuticals

July 21, 2025

Cooley advised Blue Owl (NYSE: OWL), a leading asset manager redefining alternatives, on an up to $500 million term loan facility for Madrigal Pharmaceuticals (NASDAQ: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis.

Read more

Related contacts

Michael Tollini
Partner, Washington, DC
Addison Pierce
Partner, Chicago
Dr. Jon Cousin
Partner, Washington, DC
Geoffrey Spolyar
Partner, Boston
Xander Lee
Partner, Santa Monica
Phil Mitchell
Partner, New York
Steve Flores
Partner, Chicago
Michael Neumeister
Partner, Los Angeles
Randy Sabett
Special Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC
Natasha Leskovsek
Of Counsel, Washington, DC
Wyatt Kernell
Associate, Colorado
Dr. Asako Kubota
Associate, Washington, DC
Allison Kutner
Associate, New York
Amanda Pacheco
Associate, Palo Alto
Charles A. Watkins II
Associate, Santa Monica
Jeffery Wyzykowski
Patent Agent, Washington, DC
Margie Murphy
Paralegal Specialist, New York

Related Practices & Industries

Blue Owl Capital Invests up to $262.5 Million in ITM Isotope Technologies Munich SE

May 27, 2025

Cooley advised Blue Owl Capital (NYSE: OWL), an asset manager redefining alternatives, on an up to $262.5 million term loan facility for ITM Isotope Technologies Munich SE, a radiopharmaceutical biotech company dedicated to providing a new generation of radiopharmaceutical therapeutics and diagnostics for hard-to-treat tumors.

Read more

Related contacts

Michael Tollini
Partner, Washington, DC
Addison Pierce
Partner, Chicago
Dr. Jon Cousin
Partner, Washington, DC
Geoffrey Spolyar
Partner, Boston
Xander Lee
Partner, Santa Monica
Phil Mitchell
Partner, New York
Steve Flores
Partner, Chicago
Susan Piascik Christoff
Special Counsel, Washington, DC
Randy Sabett
Special Counsel, Washington, DC
Karen Tsai
Special Counsel, Washington, DC
Natasha Leskovsek
Of Counsel, Washington, DC
Wyatt Kernell
Associate, Colorado
Matt Kong
Associate, San Francisco
Dr. Asako Kubota
Associate, Washington, DC
Allison Kutner
Associate, New York
Amanda Pacheco
Associate, Palo Alto
Charles A. Watkins II
Associate, Santa Monica
Jennifer Fitzpatrick
Paralegal Specialist, Washington, DC
Margie Murphy
Paralegal Specialist, New York
Larry Teague
Patent Agent, Seattle

Related Practices & Industries

Manage the global patent portfolio of Usher III Initiative

June 23, 2016

Cooley manages the global patent portfolio of Usher III Initiative, Inc., a research consortium of leading retinal and cochlear specialists established to develop treatments for Usher Syndrome Type III.  Usher Syndrome is a genetic disorder that causes progressive hearing and vision loss and affects less than 0.01% of the population worldwide. Cooley’s work has resulted in the issuance of US and foreign patents covering small-molecule therapeutics showing promise as drugs useful for treating Usher Syndrome Type III.

Related contacts

Dr. Matthew Langer
Senior Counsel , New York
Dr. Asako Kubota
Associate, Washington, DC

Related Practices & Industries

Admissions and credentials

District of Columbia

Registered to practice before the United States Patent and Trademark Office (USPTO)

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.